CAS: 58066-85-6; Hexadecyl (2-(Trimethylammonio)Ethyl) Phosphate

上下游产品

2-bromoethyl hexadecyl hydrogen phosphate trimethylamine 2-hexadecyloxy-[1,3,2]dioxaphospholane 2-oxide 1-Hexadecanol4-azido-2,3,5,6-tetrafluorobenzoic acid

1-十六烷醇置于碘体系中,用 二氯甲烷,乙腈 作为反应溶剂,化学反应 0.75H,反应生成 米替福星
参考文献:有效合成胆碱磷酸磷脂头基.
标题:有效合成胆碱磷酸磷脂头基.
摘要:为了寻找在温和条件下(其中二酰基甘油部分不被氧化)在磷脂中制备胆碱磷酸酯头基的有效方法,开发了一种使用亚磷酸三烷基酯和i 2进行磷酸化的方法.活性中间体是通过亚磷酸被i 2氧化而形成的磷酰碘.通过一锅反应,将2-溴乙醇,二甲基氯代亚磷酸二甲酯和醇(甘油二酯)高产率地转化为磷酸三酯.在第二反应中,将磷酸三酯脱甲基,并通过用三甲胺水溶液处理将乙基溴基转化为胆碱.该方法适用于十六烷基磷酸胆碱和1,2-二癸酰基-1-脱氧-1-硫代-Sn-甘油-3-磷酸胆碱的合成.
DOI:10.1016/s0009-3084(00)00224-3

专利信息

专利号:WO-2024220674-A1
优先权日:2023-04-18
标题:Timescale-guided microfluidic synthesis of polyphenol-iron iii network nanocapsules of hydrophobic drugs
发明人：YEO YOON; HAN BUMSOO; SHEN YINGNAN
权利人:PURDUE RESEARCH FOUNDATION
摘要:A scalable method of continuous microfluidic synthesis of tannic acid-iron III (TA-FeIII) network (TFN) nanocapsules of a hydrophobic drug; a scalable method of continuous microfluidic synthesis of epigallocatechin-3-gallate iron III (EGCG-FeIII) network, (EFN) nanocapsules; hydrophobic drug nanocapsules synthesized in accordance with the method; and a method of administering a hydrophobic drug to a patient in need thereof by administering to the patient the hydrophobic drug nanocapsules.

专利号:US-2023398215-A1
优先权日:2020-10-28
标 题:Genetically engineered antigen-specific natural killer cells for in situ synthesis of proteins
发明人：BHATNAGAR PARIJAT
权利人:STANFORD RES INST INT
摘要:An example genetically engineered natural killer (NK) cell comprises an exogenous polynucleotide sequence that includes a receptor element, an actuator element, and an effector element. The receptor element encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain operably linked to a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain recognizes a surface antigen of a target cell. The actuator element encodes a transcription factor binding site that upregulates synthesis of an effector protein. The effector element encodes the effector protein operably linked to a signal peptide, wherein, in response to the antigen binding domain of the CAR binding to the antigen of the target cell, the engineered NK cell is configured to activate and, to synthesize and secrete the effector protein.

专利号:US-11672829-B2
优先权日:2015-09-10
标 题:Genetically engineered coronavirus-specific effector cells for in situ synthesis of antiviral proteins
发明人：BHATNAGAR PARIJAT; SSEMADAALI MARVIN A
权利人:STANFORD RES INST INT
摘要:An example genetically engineered effector cell comprises an exogenous polynucleotide sequence that includes a receptor element, an actuator element, and an effector element. The receptor element encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain operably linked to a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain recognizes an antigen on a surface of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-infected cell. The actuator element encodes a transcription factor binding site that upregulates synthesis of an antiviral protein. The effector element encodes the antiviral protein operably linked to a signal peptide, wherein, in response to the antigen binding domain of the CAR binding to the antigen of SARS-CoV-2-infected cell, the engineered effector cell is configured to activate and, to synthesize and secrete the antiviral protein.

专利号:US-2024101632-A1
优先权日:2021-01-27
标 题:Genetically engineered electrically-stimulated effector cells for in situ synthesis of proteins
发明人：BHATNAGAR PARIJAT; NEWMYER SHERRI
权利人:STANFORD RES INST INT
摘要:An example genetically engineered electrically-stimulated (ES) cell comprises an exogenous polynucleotide sequence that includes an electrical-sensor element, an actuator element, and an effector element. The electrical-sensor element encodes a voltage-gated calcium ion channel (CaV), wherein the CaV is configured to transition from a closed state to an open state in response to stimulation. The actuator element encodes a transcription factor binding site that upregulates synthesis of an effector protein. The effector element encodes the effector protein, wherein, in response to the transition of the CaV to the open state, the genetically engineered ES effector cell is configured to activate and, to synthesize and secrete the effector protein.

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-7893286-B2
优先权日:2007-06-01
标题 :Method for the synthesis of phospholipid ethers
发明人：PINCHUK ANATOLY; WEICHERT JAMEY P; LONGINO MARC
权利人:CELLECTAR INC
摘要:Disclosed are improved methods for the synthesis of phospholipid ether analogs and alkyl phosphocholine analogs. The methods allow greater versatility of the reactants used and greater ease in synthesizing alkyl chains of varying length while affording reaction temperatures at room temperature or below. The methods disclosed herein provide reactants and conditions using alkyl halides and organozinc reagents and do not utilize Gringard reactions thus, allowing greater ease of their separation and purity of products. The PLE compounds synthesized by the methods disclosed herein can also be used for synthesizing high specific activity phospholipid ether (PLE) analogs, for use in treatment and diagnosis of cancer.